Status:
COMPLETED
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
Lead Sponsor:
CancerCare Manitoba
Collaborating Sponsors:
The Hospital for Sick Children
Novo Nordisk A/S
Conditions:
Hemophilia A
Eligibility:
MALE
3-20 years
Brief Summary
The is study will examine whether variation in clinical bleeding frequency and severity among boys with severe Hemophilia A (Factor VIII deficiency) is associated with variations in laboratory measure...
Eligibility Criteria
Inclusion
- documented circulating FVIII level of ≤1%
- age 3 - 20 years
- may be on primary or secondary prophylaxis
- granting of informed consent
Exclusion
- measurable inhibitor level at the time of enrollment
- ingestion of aspirin/supplement known to influence platelet function within 14 days of blood sampling, or ibuprofen within 3 days
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT02225483
Start Date
September 1 2014
End Date
December 1 2016
Last Update
February 3 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
2
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8